24
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Dorzolamide x Apraclonidine in the prevention of the intraocular pressure spike after Nd : YAG laser posterior capsulotomy

, , , , &
Pages 237-241 | Published online: 02 Jul 2009

References

  • Steinert RF, Puliafito CA, Kumar SR, Dudak SD, Patel S. Cystoid macular edema, retinal detachment and glaucoma after Nd: YAG laser posterior capsulotomy. Am J Ophthal-mol. 1991;112:373–380.
  • Altamirano D, Guex-Crosier Y, Hovey E. Complications de la capsulotomie postérieure au Nd: YAG laser. Etude de 226 cas. Klin Monatsbl Augenheilkd. 1994;204:286–287.
  • Slomovic AR, Parrish RK. Acute elevation of intraocular pressure following Neodymium YAG laser posterior capsu-lotomy. Ophthalmology. 1985;92:973–975.
  • Jahn CE, Emke M. Long term elevation of intraocular pres-sure after Neodymium: YAG Laser posterior capsulotomy. Ophthalmologica. 1996;210:85–89.
  • Fourman S, Apisson J. Late onset elevation in intraocular pressure after Neodymiun YAG laser posterior capsulo-tomy. Arch Ophthalmol. 1991;109:511–513.
  • Wetzel W. Ocular aqueous dynamics after photodisruptive laser surgery procedures. Ophthalmic Surg. 1994;25:298–302.
  • Altamirano D, Mermoud A, Pittet N. Aqueous humor analysis after Nd: YAG laser posterior capsulotomy with the laser flare cell meter. J Cataract Refract Surg. 1992;18: 554–558.
  • Richter CU, Arzeno G, Pappas HR. Prevention of intraoc-ular pressure elevation following Neodymium : YAG laser posterior capsulotomy. Arch Ophthalmol. 1985;103:912–915.
  • Pollack IP. Brown RH, Crandall AS. Prevention of the rise following Neodymium YAG laser posterior capsulotomy using topical 1% Apraclonidine. Arch Ophthalmol. 1988; 106: 754–757.
  • Brown RH, Stewart RH, Lynch MG, Higgingbotham EJ. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology. 1988; 95(3):378–384.
  • Robin AL. Short-term effects of unilateral 1% apracloni-dine therapy. Arch Ophthalmol. 1988;106:912–915.
  • Coleman AL, Robin AL, Pollack IP Cardiovascular and intraocular pressure effects and plasma concentrations ofapraclonidine. Arch Ophthalmol. 1990 ;108: 1264–1267.
  • Jampel HD, Robin AL, Quigley HA. Apraclonidine: A one-week dose response study. Arch Ophthalmol. 1988;106: 1069–1073.
  • Robin AL. Short term effects of unilateral apraclonidine therapy. Arch Ophthalmol. 1988;106:912–915.
  • Wang RF, Serle JB, Pods SM, Sugrue MF. MK 507, a topi-cally active carbonic anhidrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991; 109:1297–1299.
  • Pfeiffer N. Dorzolamide: Development and clinical appli-cation of a topical carbonic anhydrase inhibitor. Survey of Ophthalmology. 1997;42:137–150.
  • Lippa EA, Carlson LE, Yttenborg J. Dose response and duration of action of dorzolamide, a topical carbonic anhidrase inhibitor. Arch Ophthalmol. 1992;110 :495–499.
  • Lippa EA, Schuman JS, Wilensky JT. MK 507 versus sezo-lamide. Ophthalmology. 1991 ;98(3): 308–313.
  • Maus TL, Larsson L, McLaren JAM Comparison of dorzolamide and acetazolamide as supressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45–49.
  • Centofanti M, Manni GL, Napoli D, Bucci MG. Compara-tive effects on intraocular pressure between systemic and topical carbonic anhydrase inhibitors: A clinical masked, cross-over study. Pharmacological Research. 1997;35: 481–484.
  • Rosenberg LF, Krupin T, Tang L. Combination of systemic acetazolamide and topical dorzolamide in reducing intraoc-ular pressure and aqueous humor formation. Ophthalmol-ogy. 1998;105:88–93.
  • Wilkerson M, Cyrlin M, Lippa EA. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 1993;111: 1343–1349.
  • Larsson L, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazo-lamide. Arch Ophthalmol. 1998;116:19–24.
  • Arieta CEL, Barbosa KB, Rocha EM, Castro RS, José NK. Pilocarpina a 2% na prevencão da elevacdo da pressão intra-ocular pela aplicacdo de Neodymium YAG Laser em capsulotomia posterior. Arq Bras Oftal. 1993;56: 266–268.
  • Brown SL, Thomas JV, Belcher CD, Simmons RJ. Effect of pilocarpine in treatment of intraocular pressure elevation following Neodymium : YAG laser posterior capsulotomy. Ophthalmology. 1985;92:354–359.
  • Silverstone DE, Novack GD, Kelley EP, Chen KS. Pro-phylactic treatment of intraocular pressure elevations after Neodymium : YAG laser posterior capsulotomies and cataract extractions with levobunolol. Ophthalmology. 1988;95:713–718.
  • Migliori ME, Beckman H, Channel MM. Intraocular pres-sure changes after Neodymium YAG laser capsulotomy in eyes pretreated with timolol. Arch Ophthalmol. 1987;105:473–475.
  • Loewenstein A, Varssano D, Lazar M, Geyer 0. Prevention of the rise in intraocular pressure following Neodymium YAG laser posterior capsulotomy using topical clonidine. Acta Ophthalmologica. 1991;69 :462–465.
  • Ladas ID, Pavlopoulos GP, Kokolakis SN, Theodossiadis GP. Prophylactic use of acetazolamide to prevent intraocu-lar pressure elevation following Neodymium YAG laser posterior capsulotomy. Br J of Ophthalmology. 1993;77: 136–138.
  • Cullom Jr, RD, Schwartz LW. The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd: YAG laser posterior capsulotomy. Ophthalmic Surg. 1993 ;24(9):623–626.
  • Silverstone DE, Brint SF, Burk LL. Prophylactic use of ap-raclonidine for intraocular pressure increase after Nd : YAG capsulotomies. Am J Ophthalmol. 1992;113:401–105.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.